Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03053050 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 808
- Enrollment target
NCT03053050 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 808 participants.
The verdict
NCT03053050, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 808 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
Interventions
- DRUG SEL
- DRUG Placebo to match SEL 6 mg
- DRUG Placebo to match SEL 18 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 808 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03053050
The ClinicalTrials.gov registry entry for NCT03053050 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 808 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which SEL is the first listed.
NCT03053050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03053050 about?
NCT03053050 is a clinical study titled "Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis". The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
What is the current status of trial NCT03053050?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 808 participants. The study started on 2017-02-13. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT03053050?
The interventions under investigation include: SEL (DRUG), Placebo to match SEL 6 mg (DRUG), Placebo to match SEL 18 mg (DRUG).
Who is sponsoring clinical trial NCT03053050?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.